• Skip to main content
Herophilus

Herophilus

Herophilus, is a San Francisco-based neurotherapeutics company that employs phenotypic screening to discover novel drugs for complex neurological and psychiatric diseases.

  • Home
  • Approach
  • Pipeline
  • Media
  • Team
  • Careers

Recent Events

Learn how Herophilus optimizes the scaling of patient-derived brain organoids to uncover deep phenotypes of disease in our latest bioRxiv preprint.

System1 Biosciences CTO Doug Flanzer discusses AWS technology and its role in our neurotherapeutics discovery pipeline at AWS HCLS 2020.

System1 Biosciences Co-Founder Sean Escola speaks about our mission at Brain Mind 2019.

In the News

email: press {at} herophilus {dot} com

WALL STREET JOURNAL – SEPTEMBER 12, 2018
Startup Uses ‘Mini Brains’ and Software to Power Drug Research

SERIES A PRESS RELEASE – SEPTEMBER 12, 2018
System1 announces Series A funding, led by Pfizer Ventures and Charles River Ventures

© 2016-2021 Herophilus. All Rights Reserved.

  • Approach
  • Media
  • Team
  • Careers